<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of peripheral psoriatic arthritis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of peripheral psoriatic arthritis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of peripheral psoriatic arthritis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher Ritchlin, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alexis Ogdie, MD, MSCE</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joachim Sieper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 22, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H389921745"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Psoriatic arthritis (PsA) affects multiple domains, including peripheral arthritis, axial arthritis, dactylitis, enthesitis, skin, and nails. The severity of involvement ranges from mild to severe, with some patients experiencing advanced joint damage and functional disability.</p><p>Treatment of PsA requires coordinated intervention to address all domains of this disease. It is essential to thoroughly evaluate patients for involvement in each of these domains to develop a comprehensive treatment regimen. In addition, multiple comorbidities are associated with PsA and often negatively impact therapeutic response.</p><p>The choice of therapy for peripheral arthritis is based on the severity of disease and the patient's response to treatment. It may also be influenced by comorbidities, patient goals and preferences regarding cost and route of drug administration, and regulatory and insurance requirements.</p><p>The choice of treatment also depends, in part, on whether the patient has active psoriasis as well as arthritis, especially when the psoriasis has a major negative impact on the patient.</p><p>The drugs used for the peripheral arthritis of PsA overlap with the agents prescribed for other forms of inflammatory arthritis, such as spondyloarthritis and rheumatoid arthritis. However, patients with these diagnoses may experience markedly different responses to the same drugs.</p><p>The treatment of the peripheral arthritis of PsA is discussed in this topic review. The treatment of other manifestations of psoriasis and PsA, the clinical manifestations and diagnosis of PsA, and the pathogenesis of PsA are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7793.html" rel="external">"Treatment of psoriatic arthritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5666.html" rel="external">"Treatment of psoriasis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/96391.html" rel="external">"Nail psoriasis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7784.html" rel="external">"Clinical manifestations and diagnosis of psoriatic arthritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7791.html" rel="external">"Pathogenesis of psoriatic arthritis"</a>.)</p><p></p><p class="headingAnchor" id="H2561583649"><span class="h1">DISEASE SEVERITY DEFINITIONS</span><span class="headingEndMark"> — </span>For purposes of this topic review, we define disease severity using the groups below. However, we recognize that there is substantial heterogeneity in psoriatic arthritis (PsA) and that these definitions may not be a perfect fit for a given patient.</p><p>In particular, functional limitation is an important component to disease assessment and is highly dependent on the individual patient. The impact of the same objective findings on a patient’s quality of life may vary dramatically between patients and may depend on the patient’s vocation, treatment goals, and other issues. However, we believe that these definitions provide a useful framework for therapeutic decisions.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minimal disease</strong> – Patients with intermittent joint symptoms that do not significantly impact the patient’s activities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild disease</strong> – Patients with mild peripheral PsA typically fall into one of two groups:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who meet the following characteristics:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Up to three joints affected by PsA</p><p class="bulletIndent3"><span class="glyph">-</span>No joint damage</p><p class="bulletIndent3"><span class="glyph">-</span>No significant impact on function or quality of life</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with intermittent joint involvement that has failed to respond to nonsteroidal antiinflammatory drugs (NSAIDs)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate to severe disease</strong> – Patients with moderate to severe peripheral PsA typically fall into one of two groups:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with highly active disease (eg, multiple involved joints, erosive disease at presentation, functional limitation)</p><p class="bulletIndent2"><span class="glyph">•</span>Patients with a mild disease presentation who fail to improve after three months of treatment (see <a class="local">'Treatment options'</a> below)</p><p></p><p>Clinical trials frequently define treatment efficacy using American College of Rheumatology (ACR) response criteria  (<a class="graphic graphic_table graphicRef64036" href="/d/graphic/64036.html" rel="external">table 1</a>) or the Psoriasis Area and Severity Index (PASI). These response criteria are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7494.html" rel="external">"Assessment of rheumatoid arthritis disease activity and physical function", section on 'ACR response criteria'</a> and  <a class="medical medical_review" href="/d/html/5666.html" rel="external">"Treatment of psoriasis in adults"</a>.)</p><p class="headingAnchor" id="H3376714532"><span class="h1">MINIMAL DISEASE</span><span class="headingEndMark"> — </span>For patients with minimal disease, we suggest initiating treatment with symptomatic therapies such as a nonsteroidal antiinflammatory drug (NSAID) [<a href="#rid1">1,2</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Available options</strong> – NSAIDs that we use in patients with peripheral arthritis include <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> (375 to 500 mg twice daily), <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a> (200 mg twice daily), <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> (up to 2400 mg daily), <a class="drug drug_general" data-topicid="9348" href="/d/drug information/9348.html" rel="external">diclofenac</a> (up to 150 mg daily), <a class="drug drug_general" data-topicid="8590" href="/d/drug information/8590.html" rel="external">ketoprofen</a> (up to 200 mg daily), or <a class="drug drug_general" data-topicid="10295" href="/d/drug information/10295.html" rel="external">meloxicam</a> (up to 15 mg daily)  (<a class="graphic graphic_table graphicRef70067" href="/d/graphic/70067.html" rel="external">table 2</a>). The cyclooxygenase 2 (COX-2) selective inhibitor etoricoxib can also be given in a once-daily dose of 60 or 90 mg but is not available in the United States or Canada.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>NSAID efficacy</strong> – There is general consensus by experts that NSAIDs, including both nonselective NSAIDs (eg, <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a>) and COX-2 selective NSAIDs (eg, <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a>), can help control the mild inflammatory symptoms of psoriatic arthritis (PsA) and may also lessen pain and stiffness in spondylitis, although there is very limited evidence from randomized trials in patients with PsA [<a href="#rid1">1-5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>NSAID comparative efficacy</strong> – Comparative studies have not found any difference in efficacy between different NSAIDs. As a result, the choice of an NSAID depends upon the individual clinician's familiarity with a particular drug, patient preference regarding frequency of administration, and individual patient tolerance and comorbidities (eg, cardiovascular or peptic ulcer disease).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>NSAID contraindications</strong> – Many patients with PsA have an increased risk of cardiovascular disease. NSAIDs may add to that risk.</p><p></p><p class="bulletIndent1">While there has been some concern that NSAIDs may aggravate the cutaneous manifestations of psoriasis [<a href="#rid6">6,7</a>], in one randomized trial of a COX-2 selective inhibitor, no significant difference in skin involvement was noted between the two groups [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1">Other concerns regarding the safety of NSAIDs are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7968.html" rel="external">"NSAIDs: Adverse cardiovascular effects"</a> and  <a class="medical medical_review" href="/d/html/7991.html" rel="external">"Nonselective NSAIDs: Overview of adverse effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternatives to NSAID</strong> – In patients with only one or two swollen joints (ie, mono- or oligoarthritis), we generally perform a joint aspiration and intraarticular glucocorticoid injection. (See  <a class="medical medical_review" href="/d/html/7986.html" rel="external">"Joint aspiration or injection in adults: Technique and indications"</a>.)</p><p></p><p class="bulletIndent1">Although there are no randomized trials demonstrating efficacy of intraarticular injections, an observational cohort study demonstrated that approximately 40 percent of patients with PsA will respond to intraarticular injections [<a href="#rid8">8</a>]. Care should be taken in patients who require intraarticular glucocorticoid injections to avoid injection through psoriatic plaques, which may introduce cutaneous flora into the joint [<a href="#rid9">9</a>]. We generally avoid the use of oral glucocorticoids. (See  <a class="medical medical_review" href="/d/html/7793.html" rel="external">"Treatment of psoriatic arthritis", section on 'Limited role of glucocorticoids'</a>.)</p><p></p><p class="headingAnchor" id="H561297886"><span class="h1">MILD DISEASE</span></p><p class="headingAnchor" id="H3163796851"><span class="h2">Treatment selection</span><span class="headingEndMark"> — </span>For patients with mild peripheral psoriatic arthritis (PsA), we suggest treating with <a class="drug drug_general" data-topicid="94524" href="/d/drug information/94524.html" rel="external">apremilast</a> or <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX).</p><p></p><p class="bulletIndent1">We prefer <a class="drug drug_general" data-topicid="94524" href="/d/drug information/94524.html" rel="external">apremilast</a> because it is generally well tolerated and does not require routine monitoring. If apremilast is not feasible, we typically use MTX. In Europe, MTX is often preferred over apremilast because of its widespread availability. However, multiple options to both apremilast and MTX exist. (See <a class="local">'Alternatives to apremilast'</a> below.)</p><p></p><p>Patients may require treatment for up to three to four months to determine maximum efficacy of these agents.</p><p>We do not use <a class="drug drug_general" data-topicid="94524" href="/d/drug information/94524.html" rel="external">apremilast</a>, MTX, <a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">leflunomide</a> (LEF), <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, or <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a> (SSZ) for patients with joint damage due to PsA. There are no studies demonstrating that these agents are effective at preventing erosive disease due to PsA. Patients with joint erosions are classified as having moderate to severe disease and should be treated with a biologic agent. (See <a class="local">'Other agents'</a> below and <a class="local">'Moderate to severe disease'</a> below.)</p><p class="headingAnchor" id="H1029075111"><span class="h2">Treatment options</span></p><p class="headingAnchor" id="H2034844948"><span class="h3">Apremilast</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration</strong> – The target dose for <a class="drug drug_general" data-topicid="94524" href="/d/drug information/94524.html" rel="external">apremilast</a> is 30 mg twice daily. We start apremilast at 10 mg daily and then increase the dose by 10 mg every day until this target dose is reached.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – <a class="drug drug_general" data-topicid="94524" href="/d/drug information/94524.html" rel="external">Apremilast</a> is an effective therapy for peripheral PsA. In a study of 504 patients with PsA, patients randomized to receive apremilast 30 mg twice daily were significantly more likely to experience improvement in their peripheral arthritis than patients treated with placebo (40 versus 19 percent). This study also noted improvements in physical function, psoriasis, and physical function associated with apremilast therapy [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="94524" href="/d/drug information/94524.html" rel="external">Apremilast</a> may be particularly appropriate for patients with the following characteristics:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Concomitant enthesitis and dactylitis</strong> – <a class="drug drug_general" data-topicid="94524" href="/d/drug information/94524.html" rel="external">Apremilast</a> has efficacy against both manifestations, particularly early in the disease course. (See  <a class="medical medical_review" href="/d/html/7793.html" rel="external">"Treatment of psoriatic arthritis", section on 'Enthesitis and dactylitis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Concomitant psoriasis</strong> – The beneficial impact on skin disease appears similar to MTX, but the drugs have not been directly compared.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Multiple comorbidities</strong> – Given the excellent safety profile of <a class="drug drug_general" data-topicid="94524" href="/d/drug information/94524.html" rel="external">apremilast</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions</strong> – Routine laboratory monitoring is not required. However, the following precautions should be considered:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic kidney disease</strong> – The dose should be reduced to 30 mg once daily in patients with creatinine clearance estimated at less than 30 mL/min.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Weight loss</strong> – Patients treated with <a class="drug drug_general" data-topicid="94524" href="/d/drug information/94524.html" rel="external">apremilast</a> should have their weight monitored regularly, as significant weight loss may require discontinuation of treatment [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Depression</strong> – Use of <a class="drug drug_general" data-topicid="94524" href="/d/drug information/94524.html" rel="external">apremilast</a> has also been associated with an increase in reports of depression compared with placebo [<a href="#rid12">12</a>].</p><p></p><p class="headingAnchor" id="H4042001555"><span class="h3">Alternatives to apremilast</span></p><p class="headingAnchor" id="H420305186"><span class="h4">Methotrexate</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration</strong> – Oral MTX is initiated at 10 mg once weekly and should be increased over the next two to four weeks to 20 mg once weekly.</p><p></p><p class="bulletIndent1">In patients with an inadequate response to oral MTX greater than 17.5 mg weekly, we switch to the subcutaneous route, which improves absorption of the medication. Alternatively, splitting the oral dose into three doses administered over a 24-hour period (eg, morning, evening, and the next morning) may improve pharmacokinetics and pharmacodynamics. (See  <a class="medical medical_review" href="/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis", section on 'Dosing and administration'</a>.)</p><p></p><p class="bulletIndent1">Subcutaneous MTX can be increased up to 25 or, rarely, 30 mg weekly. With the correct dose, a response should occur within eight weeks of initiating therapy. The maximal response to MTX is usually achieved within three months of treatment with the drug. Patients who do not respond to MTX 25 mg weekly for six to eight weeks are unlikely to respond to more prolonged therapy or higher doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Observational studies and our clinical experience indicate that MTX may be effective for some patients with peripheral PsA [<a href="#rid13">13-15</a>]. Expert opinion also supports use of MTX for the treatment of peripheral PsA, including treatment guidelines of the European Alliance of Associations for Rheumatology (EULAR; formerly known as European League Against Rheumatism) [<a href="#rid4">4,16</a>] and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) [<a href="#rid5">5,17</a>]. We use it as well based upon ease of use, tolerability, proven efficacy in psoriasis, and long and extensive experience from the treatment of rheumatoid arthritis.</p><p></p><p class="bulletIndent1">However, most randomized trials and other studies have not shown significant benefit to MTX for the treatment of peripheral PsA. These clinical trials have all had significant limitations, including the use of lower doses of MTX than are routinely used in practice; patient populations with very longstanding disease; small numbers of subjects; trials of short duration; and other elements of poor study design [<a href="#rid14">14,18</a>].</p><p></p><p class="bulletIndent1">For example, in the Study of <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">Etanercept</a> and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> in Subjects with Psoriatic Arthritis (SEAM-PsA Study), a randomized trial that compared MTX monotherapy with etanercept monotherapy and the combination of etanercept and MTX, MTX appeared to inhibit radiographic progression, but the magnitude of inhibition was significantly less than that observed with etanercept [<a href="#rid18">18</a>]. Furthermore, the absence of a placebo arm complicates the interpretation of these data.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions</strong> – In patients with psoriasis who have obesity or diabetes, MTX is associated with an increased risk of hepatic fibrosis [<a href="#rid19">19,20</a>]. Precautions for the use of MTX and prevention of adverse effects are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis", section on 'Precautions and prevention of adverse effects'</a>.)</p><p></p><p class="headingAnchor" id="H2173604013"><span class="h4">Other agents</span><span class="headingEndMark"> — </span>For patients who are unable to use either <a class="drug drug_general" data-topicid="94524" href="/d/drug information/94524.html" rel="external">apremilast</a> or MTX, other reasonable options include LEF and <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>. Cyclosporine has some efficacy for psoriasis and arthritis, whereas LEF generally is less beneficial for the skin disease.</p><p></p><p class="bulletIndent1">We do not typically use SSZ for peripheral PsA, given limited data supporting its use for this indication and our own clinical experience [<a href="#rid21">21,22</a>].</p><p></p><p>For patients whose disease is not well controlled with one of these agents, we typically treat with a tumor necrosis factor (TNF) inhibitor. (See <a class="local">'TNF inhibitors for most patients'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">Leflunomide</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dosing and administration</strong> – LEF (20 mg daily, taken orally) can also be prescribed as a first-line therapy for patients with a low skin burden of psoriasis.</p><p></p><p class="bulletIndent2">We do not use a loading dose, as reported in some studies [<a href="#rid23">23</a>], because of the higher rate of gastrointestinal side effects with this approach.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Efficacy</strong> – The benefits of LEF in patients with PsA have been shown in a small number of randomized trials and observational studies [<a href="#rid23">23-27</a>]. In our experience, LEF is effective in approximately 40 percent of patients. It also improves skin disease but may be less effective for the skin than MTX [<a href="#rid27">27</a>]. Treatment for a total of three months is usually adequate to determine the maximal degree of benefit. Effects on progression of radiologic joint damage have not been demonstrated.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Precautions</strong> – Details regarding adverse effects associated with LEF are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7515.html" rel="external">"Pharmacology, dosing, and adverse effects of leflunomide in the treatment of rheumatoid arthritis", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">Cyclosporine</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dosing and administration</strong> – <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">Cyclosporine</a> is used in lower doses for psoriasis and PsA than for organ transplantation. Most patients receive between 2.5 and 5 mg/kg daily orally, usually divided into two to three doses daily.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Efficacy</strong> – Evidence for the efficacy of <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> for PsA includes the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>An open-label trial randomized 99 patients with PsA to treatment with <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> (3 mg/kg daily) versus SSZ (2000 mg daily) versus "usual care" (ie, nonsteroidal antiinflammatory drugs [NSAIDs], low-dose <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, and analgesics). This study demonstrated only very modest benefit to cyclosporine compared with the other treatments [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A blinded trial randomized 72 patients with PsA who had an incomplete response to MTX to receive either <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> or placebo. The addition of cyclosporine to MTX was associated with significant improvements in the number of swollen joints and C-reactive protein compared with patients receiving placebo [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">Cyclosporine</a> is also an effective agent for psoriatic skin disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Precautions</strong> – Use of <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> has been largely supplanted by other more potent and safer therapies for the treatment of PsA. Kidney toxicity is a limiting factor, and kidney function and blood pressure need to be closely monitored. (See  <a class="medical medical_review" href="/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">Sulfasalazine</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dosing and administration</strong> – SSZ is started at 500 mg daily and gradually increased over a period of several days to a maximum of 1000 to 1500 mg twice daily.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Efficacy</strong> – The available evidence, including randomized trial data [<a href="#rid21">21,30-32</a>], suggests only limited benefit for the joint and even less for skin disease, although improvement can be seen in both domains [<a href="#rid21">21,30,33-35</a>].</p><p></p><p class="bulletIndent2">The largest study of SSZ in PsA randomly assigned 221 patients with PsA to SSZ (2 g daily) or placebo [<a href="#rid34">34</a>]. Using the Psoriatic Arthritis Response Criteria (PsARC) to identify patients who responded to the medication, the response rate was higher in the SSZ group than in the placebo group (58 versus 45 percent), but the effect size was small.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Precautions</strong> – Adverse effects may be a limiting factor for the use of SSZ. In one study, 40 percent of patients discontinued SSZ within three months [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent2">The major reasons for discontinuation of therapy are gastrointestinal side effects. In addition, the onset of drug-induced lupus and toxic epidermal necrolysis has been described in patients with psoriasis treated with SSZ [<a href="#rid36">36,37</a>].</p><p></p><p class="bulletIndent2">The dose of SSZ required to control PsA may be higher than the dose needed for RA. As a result, many patients with PsA do not tolerate SSZ, although it is effective in some patients [<a href="#rid21">21,30,34,35</a>].</p><p></p><p class="bulletIndent2">Patients with sulfa allergy should not take SSZ. Routine monitoring of laboratory tests, as in patients with rheumatoid arthritis, is required, as SSZ may lead to leukopenia. (See  <a class="medical medical_review" href="/d/html/7524.html" rel="external">"Sulfasalazine: Pharmacology, administration, and adverse effects in the treatment of rheumatoid arthritis", section on 'Adverse effects'</a>.)</p><p></p><p class="headingAnchor" id="H2072387780"><span class="h1">MODERATE TO SEVERE DISEASE</span></p><p class="headingAnchor" id="H1578401369"><span class="h2">TNF inhibitors for most patients</span><span class="headingEndMark"> — </span>For patients with moderate to severe disease, we suggest a tumor necrosis factor (TNF) inhibitor. These agents are generally the first-line therapy in this setting because of the greater experience that exists with TNF inhibitors compared with the newer agents, as well as the greater number of trials providing evidence of benefit.</p><p>This approach is also supported by the 2015 and 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the 2020 European Alliance of Associations for Rheumatology (EULAR) recommendations [<a href="#rid4">4,5,38</a>]. However, evidence is accumulating that the other biologic agents are as effective as TNF inhibitors for the peripheral joints [<a href="#rid16">16,39-41</a>].</p><p>For patients who cannot use TNF inhibitors, we use one of the other biologic agents discussed below. (See <a class="local">'Failure of initial TNF inhibitor'</a> below.)</p><p><a class="drug drug_general" data-topicid="94524" href="/d/drug information/94524.html" rel="external">Apremilast</a> may also be used by patients trying to avoid biologic agents, but it may be less effective for more active disease [<a href="#rid10">10,42</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of TNF inhibitor</strong> – All five of the original TNF inhibitors (<a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a>, <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8644" href="/d/drug information/8644.html" rel="external">certolizumab pegol</a>, and <a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">golimumab</a>) are available for use in patients with psoriatic arthritis (PsA) in the United States, Canada, the European Union, and many other countries.</p><p></p><p class="bulletIndent1">The efficacy of the drugs for the arthritis appears comparable, and the choice of agent is based upon patient preferences for route (subcutaneous versus intravenous) and frequency of administration; regulatory and payor requirements and limitations; and potential cost to the patient.</p><p></p><p class="bulletIndent1">The choice of agent should be made in collaboration with the patient's dermatologist.</p><p></p><p class="bulletIndent1">In addition, the presence of uveitis or inflammatory bowel disease will influence the choice and dose of TNF inhibitor. (See  <a class="medical medical_review" href="/d/html/5592.html" rel="external">"Uveitis: Treatment", section on 'Anti-tumor necrosis factor-alpha'</a> and  <a class="medical medical_review" href="/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults", section on 'Choice of anti-TNF agent'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TNF inhibitor dose and administration</strong> – The five original TNF inhibitors and common dosing regimens are listed below and summarized in the table  (<a class="graphic graphic_table graphicRef143868" href="/d/graphic/143868.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">Etanercept</a> – 50 mg as a subcutaneous injection once weekly. Etanercept is a dimeric p75 TNF-alpha receptor Fc fragment fusion protein that binds TNF. An initial dose of 50 mg twice weekly for the first three months of therapy may be used in patients requiring treatment for moderate to severe psoriasis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">Infliximab</a> – 5 mg/kg administered by intravenous infusion at zero, two, and six weeks, followed by 5 mg/kg every eight weeks thereafter. It should be given with <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) to prevent the development of anti-drug antibodies. Infliximab is a human-mouse chimeric anti-TNF-alpha antibody.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">Adalimumab</a> – 40 mg subcutaneously once every two weeks. It should be given with MTX to prevent the development of anti-drug antibodies. Adalimumab is a human monoclonal anti-TNF antibody.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">Golimumab</a> – 50 mg subcutaneously once monthly. Golimumab is a human monoclonal anti-TNF antibody.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8644" href="/d/drug information/8644.html" rel="external">Certolizumab pegol</a> – Initial dose of 400 mg (administered as two 200 mg injections subcutaneously). This dose is repeated two and four weeks after the initial dose, followed by a maintenance dose of 200 mg once every other week or 400 mg every four weeks. If the patient has moderate to severe psoriasis, then the dose is 400 mg every other week. Certolizumab pegol is a pegylated Fab fragment of a humanized anti-TNF monoclonal antibody.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy of TNF inhibitors</strong> – The efficacy of the TNF inhibitors in patients with PsA has been well documented in meta-analyses [<a href="#rid43">43</a>] and in multiple clinical trials with all of these agents, including <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> [<a href="#rid44">44-47</a>], <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> [<a href="#rid6">6,48-52</a>], <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> [<a href="#rid53">53-58</a>], <a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">golimumab</a> [<a href="#rid59">59,60</a>], and <a class="drug drug_general" data-topicid="8644" href="/d/drug information/8644.html" rel="external">certolizumab pegol</a> [<a href="#rid61">61,62</a>], compared with placebo. In one retrospective analysis, monotherapy with a TNF inhibitor was superior to MTX monotherapy after controlling for multiple variables [<a href="#rid63">63</a>]. Benefits associated with TNF inhibitor therapy include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improvement in arthritis, with an American College of Rheumatology (ACR) criteria for 20 percent improvement (ACR20)  (<a class="graphic graphic_table graphicRef64036" href="/d/graphic/64036.html" rel="external">table 1</a>) response in 50 to 65 percent of patients within three months</p><p class="bulletIndent2"><span class="glyph">•</span>Reduced radiographic progression</p><p class="bulletIndent2"><span class="glyph">•</span>Improved physical function and health-related quality of life measures.</p><p></p><p class="bulletIndent1">Enthesitis, dactylitis, and cutaneous findings also improved in TNF inhibitor-treated patients. (See  <a class="medical medical_review" href="/d/html/7793.html" rel="external">"Treatment of psoriatic arthritis", section on 'Enthesitis and dactylitis'</a>.)</p><p></p><p class="bulletIndent1">Sustained benefit from these drugs has been shown in several drug registries and other studies [<a href="#rid63">63-68</a>]. As an example, in the Danish registry of 764 patients with PsA treated with their first TNF inhibitor in clinical practice, the median amount of time a patient remained compliant with that therapy (ie, drug survival) was 2.9 years. The ACR50 response rate was 45 percent.</p><p></p><p class="bulletIndent1">In addition to improvement in clinical signs and symptoms, these agents also reduce radiographic progression of disease. A meta-analysis of five randomized trials involving 1110 patients found that significantly fewer patients with PsA who were treated with TNF inhibitors (including <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a>, <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, and <a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">golimumab</a>) exhibited radiographic disease progression at week 24 of treatment compared with patients who received placebo (15 versus 31 percent) [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment considerations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Screen for latent tuberculosis</strong> – Screening for latent tuberculosis (TB) prior to beginning therapy with anti-TNF agents is necessary, and those with evidence of disease usually require prophylactic anti-TB therapy. (See  <a class="medical medical_review" href="/d/html/8017.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults without HIV infection"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transition immunosuppression</strong> – For patients already taking an oral immunosuppressive agent (eg, <a class="drug drug_general" data-topicid="94524" href="/d/drug information/94524.html" rel="external">apremilast</a>, MTX), we add the TNF inhibitor to their current regimen.</p><p></p><p class="bulletIndent2">However, in contrast to rheumatoid arthritis, MTX generally can be discontinued in patients with PsA who respond to TNF inhibitor therapy [<a href="#rid18">18</a>], with the exception of <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> and <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>, which may induce anti-drug antibodies [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent2">Evidence from registries has not shown increased efficacy with the addition of MTX to TNF inhibition. However, drug survival with combined treatment was increased slightly for most agents, most markedly for patients on <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Avoid in patients at risk of multiple sclerosis</strong> – We avoid TNF inhibitors in patients with first-degree relatives with multiple sclerosis. (See  <a class="medical medical_review" href="/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects", section on 'Demyelinating disease'</a>.)</p><p></p><p class="bulletIndent1">Details regarding adverse effects associated with TNF inhibition are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects", section on 'Adverse effects'</a>.)</p><p></p><p class="headingAnchor" id="H644248958"><span class="h1">FAILURE OF INITIAL TNF INHIBITOR</span></p><p class="headingAnchor" id="H662207837"><span class="h2">Treatment selection</span><span class="headingEndMark"> — </span>Initial treatment with a tumor necrosis factor (TNF) inhibitor may fail due to either an inadequate response (ie, primary non-response) or loss of efficacy (ie, secondary non-response). Patients may also need to stop TNF inhibitor therapy due to an adverse effect. Nonadherence due to cost or side effects may also contribute to an inadequate response. (See <a class="local">'Initial considerations'</a> below.)</p><p>If nonadherence is not an issue, the selection of the next therapeutic agent is based on several factors, including the reason for treatment failure and the disease domains that are most relevant for the patient.</p><p class="headingAnchor" id="H937254171"><span class="h3">Switch to alternative TNF inhibitor for secondary non-response</span><span class="headingEndMark"> — </span>In patients whose experience loss of efficacy following an initial response to TNF inhibition (ie, secondary non-response), we switch to a second TNF inhibitor rather than trying a different class of biologic agent.</p><p>In a patient initially treated with one of the antibody-based agents (eg, <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">golimumab</a>, or certolizumab), we prefer to switch to the soluble TNF receptor (<a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a>) and vice versa.</p><p>For patients with an elevated body mass index (BMI), intravenous, weight-based dosing with <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> or <a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">golimumab</a> may be more effective than subcutaneous administration.</p><p class="headingAnchor" id="H581502465"><span class="h3">Switch to IL-17 inhibitor for primary non-response or adverse effect</span><span class="headingEndMark"> — </span>In patients who fail to respond to TNF inhibition (primary non-response) or experience an adverse effect (eg, skin eruption, lupus-like reaction, demyelination, or infection), we use an interleukin 17 (IL-17) inhibitor such as <a class="drug drug_general" data-topicid="99569" href="/d/drug information/99569.html" rel="external">secukinumab</a>, <a class="drug drug_general" data-topicid="107448" href="/d/drug information/107448.html" rel="external">ixekizumab</a>, or <a class="drug drug_general" data-topicid="138686" href="/d/drug information/138686.html" rel="external">bimekizumab</a>. Both secukinumab and ixekizumab have been approved by the US Food and Drug Administration (FDA) for the treatment of psoriatic arthritis (PsA); bimekizumab has been approved by the FDA for the treatment of psoriasis and by the European Medicines Evaluation Agency (EMEA) for the treatment of PsA.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – These agents may be given with or without <a class="drug drug_general" data-topicid="94524" href="/d/drug information/94524.html" rel="external">apremilast</a> or <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX). Patients who are already taking apremilast or MTX should continue until the patient demonstrates a response, at which time the oral immunosuppressant may be stopped.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – IL-17 inhibitors have comparable efficacy for the treatment of the peripheral arthritis of PsA, and the choice of specific agent is based upon patient preferences, frequency of administration, regulatory and payor requirements and limitations, and potential cost to the patient.</p><p></p><p class="bulletIndent1">IL-17 inhibitors may be more efficacious for controlling severe psoriasis than TNF inhibitors [<a href="#rid72">72,73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions</strong> – IL-17 inhibitors do not require routine monitoring if they are not concomitantly administered with oral immunosuppressive agents. We screen (and treat) patients for latent tuberculosis (TB) prior to initiating treatment with IL-17 inhibitors. However, there are no data demonstrating latent TB reactivation following IL-17 blockade. (See  <a class="medical medical_review" href="/d/html/8017.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults without HIV infection"</a> and  <a class="medical medical_review" href="/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)"</a>.)</p><p></p><p class="headingAnchor" id="H594365140"><span class="h4">Secukinumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="99569" href="/d/drug information/99569.html" rel="external">Secukinumab</a> is a human anti-IL-17A monoclonal antibody that is effective for the treatment of PsA and psoriasis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration</strong> – <a class="drug drug_general" data-topicid="99569" href="/d/drug information/99569.html" rel="external">Secukinumab</a> is administered by subcutaneous injection, usually with a loading dose of 300 mg at weeks 0, 1, 2, 3, and 4, followed by 300 mg every four weeks.</p><p></p><p class="bulletIndent1">In a trial of 258 patients with PsA, patients who received <a class="drug drug_general" data-topicid="99569" href="/d/drug information/99569.html" rel="external">secukinumab</a> 300 mg every four weeks (following a loading dose) were more likely to experience improvement in their clinical joint disease after 16 weeks of treatment than patients treated with placebo (52 versus 23 percent) [<a href="#rid74">74</a>]. However, secukinumab 150 mg every four weeks was not statistically better than placebo (odds ratio [OR] 1.92, 95% CI 0.89-4.15).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – <a class="drug drug_general" data-topicid="99569" href="/d/drug information/99569.html" rel="external">Secukinumab</a> has been shown to be effective by a number of measures (eg, joint and skin symptoms, radiographic damage, physical function, quality of life) for the treatment of PsA in a series of phase 3 randomized trials [<a href="#rid75">75-77</a>]. However, patients may require up to six months of therapy to achieve their maximal response.</p><p></p><p class="headingAnchor" id="H331189279"><span class="h4">Ixekizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="107448" href="/d/drug information/107448.html" rel="external">Ixekizumab</a> is an IL-17A monoclonal antibody that has demonstrated efficacy for psoriasis and PsA.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration</strong> – <a class="drug drug_general" data-topicid="107448" href="/d/drug information/107448.html" rel="external">Ixekizumab</a> is administered by subcutaneous injection, without loading dose, at a dose of 80 mg every two weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – <a class="drug drug_general" data-topicid="107448" href="/d/drug information/107448.html" rel="external">Ixekizumab</a> has been demonstrated to be effective for PsA in clinical trials of patients who had previously been treated with an oral immunosuppressive agent or TNF inhibitor [<a href="#rid75">75,76</a>].</p><p></p><p class="bulletIndent1">In a randomized trial that compared <a class="drug drug_general" data-topicid="107448" href="/d/drug information/107448.html" rel="external">ixekizumab</a> with <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>, ixekizumab was superior for the primary outcome, which required improvement in both the peripheral arthritis and skin disease [<a href="#rid39">39,77</a>]. After 52 weeks of therapy, ixekizumab and adalimumab had similar efficacy for joint disease (American College of Rheumatology (ACR) criteria for 20 percent improvement [ACR20]  (<a class="graphic graphic_table graphicRef64036" href="/d/graphic/64036.html" rel="external">table 1</a>) 70 versus 69 percent), but ixekizumab was superior to adalimumab in controlling the skin disease (patients achieving complete clearance of all cutaneous lesions, Psoriasis Area and Severity Index [PASI100]: 64 versus 41 percent).</p><p></p><p class="headingAnchor" id="H2613926024"><span class="h4">Bimekizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="138686" href="/d/drug information/138686.html" rel="external">Bimekizumab</a>, a monoclonal antibody directed against both IL-17A and IL-17F, appears to be both safe and effective for the treatment of both psoriasis and PsA, even for patients who had previously failed therapy with TNF inhibition. Although there have not been comparative studies with other IL-17i for the treatment of PsA, the efficacy at the tested dose (160 mg) appears to be similar to the IL-17Ai. On the other hand, at the psoriasis dose (320 mg), the efficacy for bimekizumab was significantly greater than <a class="drug drug_general" data-topicid="99569" href="/d/drug information/99569.html" rel="external">secukinumab</a> (psoriasis dose 300 mg) for clearance of psoriasis (PASI100).</p><p class="bulletIndent1"><span class="glyph">●</span>BE OPTIMAL enrolled 852 patients with active PsA, who received treatment with either <a class="drug drug_general" data-topicid="138686" href="/d/drug information/138686.html" rel="external">bimekizumab</a> 160 mg every four weeks, <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> 40 mg every two weeks, or placebo [<a href="#rid78">78</a>]. After 16 weeks, patients treated with bimekizumab were more likely to achieve an ACR50 response than patients treated with placebo (43 versus 9 percent; OR 7.1, 95% CI 5.6-10.9). The ACR50 response was comparable among patients who received bimekizumab versus adalimumab (44 versus 47 percent). The PASI90 at week 16 was 61.3 percent in the bimekizumab group, 41.2 percent in the adalimumab group, and 2.9 percent in the placebo group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>BE COMPLETE enrolled 400 patients with active PsA who had previously failed therapy with at least one TNF inhibitor (either due to intolerance or lack of response) [<a href="#rid79">79</a>]. After 16 weeks, patients treated with <a class="drug drug_general" data-topicid="138686" href="/d/drug information/138686.html" rel="external">bimekizumab</a> (160 mg every four weeks) were more likely to achieve an ACR50 response (44 versus 10 percent; adjusted OR 11.1, 95% CI 5.4-23.0).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an open-label extension phase of an earlier dose-ranging study (BE ACTIVE), the efficacy of <a class="drug drug_general" data-topicid="138686" href="/d/drug information/138686.html" rel="external">bimekizumab</a> appeared to be sustained over three years of follow-up [<a href="#rid80">80-82</a>]. In all of these studies, bimekizumab was well tolerated, and the overall safety profile was similar to that reported in previous studies of this agent.</p><p></p><p class="headingAnchor" id="H819159774"><span class="h1">FAILURE OF TNF AND IL-17 INHIBITION</span></p><p class="headingAnchor" id="H3627646305"><span class="h2">Initial considerations</span><span class="headingEndMark"> — </span>In patients without an adequate response to tumor necrosis factor (TNF) and interleukin 17 (IL-17) inhibitors, we consider the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Is the diagnosis correct? Most patients will have some response to TNF or IL-17 inhibition, even if the response is inadequate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Is the patient adherent to the treatment plan?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Does the patient have concomitant fibromyalgia or central sensitization that may be responsible for the continued symptoms?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Are there other factors preventing the patient from responding (eg, depression, anxiety, obesity) that could be addressed separately?</p><p></p><p>Early identification of these issues may avoid inappropriate cycling through multiple immunosuppressive agents that are unlikely to benefit the patient.</p><p>If these issues have been excluded, and the patient requires ongoing immunosuppression, we select an agent based on the presence (or absence) of concomitant axial disease, as discussed below.</p><p class="headingAnchor" id="H3557022391"><span class="h2">Patients without concomitant axial disease</span><span class="headingEndMark"> — </span>For patients without concomitant axial disease, we suggest an IL-23 inhibitor such as <a class="drug drug_general" data-topicid="114007" href="/d/drug information/114007.html" rel="external">guselkumab</a> or <a class="drug drug_general" data-topicid="121112" href="/d/drug information/121112.html" rel="external">risankizumab</a>, both of which have been approved by the US Food and Drug Administration (FDA) for the treatment of psoriatic arthritis (PsA). For patients who cannot use an IL-23 inhibitor (eg, due to intolerance or lack of availability), <a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">ustekinumab</a> is a reasonable choice. <a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">Abatacept</a> is an option for patients who have a rheumatoid arthritis-like presentation (ie, minimal or no psoriasis and no axial disease).</p><p>These agents may be given with or without <a class="drug drug_general" data-topicid="94524" href="/d/drug information/94524.html" rel="external">apremilast</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX), <a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">leflunomide</a> (LEF), or <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, which may be discontinued if a patient responds to the combination.</p><p>Guidelines for drug monitoring are discussed in the table  (<a class="graphic graphic_table graphicRef142892" href="/d/graphic/142892.html" rel="external">table 4</a>).</p><p class="headingAnchor" id="H1337889820"><span class="h3">Guselkumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="114007" href="/d/drug information/114007.html" rel="external">Guselkumab</a>, which is effective for the treatment of moderate to severe psoriasis and for active PsA, is an anti-IL-23-specific monoclonal antibody that targets the p19-protein subunit of IL-23 [<a href="#rid83">83</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration</strong> – <a class="drug drug_general" data-topicid="114007" href="/d/drug information/114007.html" rel="external">Guselkumab</a> is administered by subcutaneous injection (100 mg, given initially and four weeks later, then every eight weeks).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The efficacy and safety of <a class="drug drug_general" data-topicid="114007" href="/d/drug information/114007.html" rel="external">guselkumab</a> for PsA has been demonstrated in randomized trials, which have evaluated patients with active PsA, some of whom had failed to respond to TNF inhibition. Guselkumab may be particularly effective for patients who have active skin disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a randomized trial involving 149 patients with active PsA and plaque psoriasis, an American College of Rheumatology (ACR) criteria for 20 percent improvement (ACR20)  (<a class="graphic graphic_table graphicRef64036" href="/d/graphic/64036.html" rel="external">table 1</a>) response at week 24 was achieved more frequently in the patients allocated to receive <a class="drug drug_general" data-topicid="114007" href="/d/drug information/114007.html" rel="external">guselkumab</a> compared with placebo (58 versus 18 percent) [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The DISCOVER 1 trial enrolled 381 patients, most of whom were naïve to biologic agents (30 percent were TNF inhibitor-experienced patients), who were randomized to placebo or <a class="drug drug_general" data-topicid="114007" href="/d/drug information/114007.html" rel="external">guselkumab</a> every four or every eight weeks. At 24 weeks, the ACR20 was achieved by more patients who received guselkumab every four weeks (59 percent) or every eight weeks (52 percent) versus placebo (22 percent) [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the DISCOVER 2 trial, which enrolled 741 TNF inhibitor-naïve patients, ACR20 response occurred in more patients who received <a class="drug drug_general" data-topicid="114007" href="/d/drug information/114007.html" rel="external">guselkumab</a> (at either frequency) versus placebo (64 versus 33 percent) [<a href="#rid86">86</a>]. The drug provided sustained benefits across multiple disease domains through one year, and the rates of adverse events, including infection, were similar in the two groups [<a href="#rid87">87</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A systematic literature review suggested that <a class="drug drug_general" data-topicid="114007" href="/d/drug information/114007.html" rel="external">guselkumab</a> has better efficacy for the skin domain of PsA than multiple other agents, including TNF inhibitors, Janus kinase (JAK) inhibitors, and <a class="drug drug_general" data-topicid="122341" href="/d/drug information/122341.html" rel="external">upadacitinib</a> [<a href="#rid88">88</a>].</p><p></p><p class="headingAnchor" id="H1618714442"><span class="h3">Risankizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="121112" href="/d/drug information/121112.html" rel="external">Risankizumab</a>, which is effective for the treatment of moderate to severe plaque psoriasis and for active PsA, is an anti-IL-23 antibody that targets the p19-protein subunit of IL-23.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration</strong> – It is administered by subcutaneous injection (150 mg, given initially and four weeks later, then every 12 weeks).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The efficacy and safety of <a class="drug drug_general" data-topicid="121112" href="/d/drug information/121112.html" rel="external">risankizumab</a> for PsA has been demonstrated in randomized trials that have evaluated patients with active PsA, some of whom had failed to respond to prior biologic therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>In biologic-naïve patients</strong> – In the randomized KEEPsAKE 1 trial, 964 patients received <a class="drug drug_general" data-topicid="121112" href="/d/drug information/121112.html" rel="external">risankizumab</a> 150 mg or placebo at weeks 0, 4, and 16. At week 24, more risankizumab-treated patients achieved an ACR20  (<a class="graphic graphic_table graphicRef64036" href="/d/graphic/64036.html" rel="external">table 1</a>) response (57.3 versus 33.5 percent) [<a href="#rid89">89</a>]. Significantly higher responses were also achieved for skin and nail psoriasis, minimal disease activity (MDA), resolution of enthesitis and dactylitis, health-related quality of life, pain, and fatigue [<a href="#rid90">90</a>]. The drug was well tolerated.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>In patients with inadequate response to biologic therapies</strong> – KEEPsAKE 2 included 444 patients randomized to <a class="drug drug_general" data-topicid="121112" href="/d/drug information/121112.html" rel="external">risankizumab</a> or placebo. Patients with previous exposure to biologics (TNF inhibitors, cytotoxic lymphocyte-associated molecule-4-immunoglobulin [CTLA-4-Ig], or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>) were included with appropriate washout periods. At week 24, more risankizumab-treated patients achieved an ACR20 response (51.3 versus 26.5 percent). Other endpoints, including change in Health Assessment Questionnaire-Disability Index (HAQ-DI), Psoriasis Area and Severity Index (PASI) 90, MDA, and Functional Assessment of Chronic Illness Therapy–Fatigue Scale (FACIT-Fatigue), also demonstrated improvement with risankizumab [<a href="#rid91">91</a>].</p><p></p><p class="headingAnchor" id="H3805868683"><span class="h3">Ustekinumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">Ustekinumab</a>, which is used for the treatment of moderate to severe plaque psoriasis and active PsA, is a human monoclonal antibody to the shared p40 subunit of IL-12 and IL-23 that interferes with receptor binding to immune cells.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration – </strong><a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">Ustekinumab</a> is administered by subcutaneous injection (45 mg, given initially and four weeks later, then every 12 weeks).</p><p></p><p class="bulletIndent1">A higher dose of <a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">ustekinumab</a> is used for patients with coexistent moderate to severe plaque psoriasis weighing greater than 100 kg (220 lbs; ie, 90 mg initially and four weeks later, followed by 90 mg every 12 weeks) [<a href="#rid92">92</a>].</p><p></p><p class="bulletIndent1">More frequent dosing is used in patients with concomitant inflammatory bowel disease (ie, every eight weeks).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy - </strong>The efficacy and safety of <a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">ustekinumab</a> for PsA has been demonstrated in randomized trials that have evaluated patients with active PsA despite prior treatment [<a href="#rid93">93-95</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>In TNF-naïve patients</strong> – A trial randomized 615 patients with PsA to treatment with either <a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">ustekinumab</a> (90 or 45 mg) or placebo every 12 weeks (following a loading dose); at week 16, patients who failed to respond underwent dose escalation [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent2">At week 24, the ACR20  (<a class="graphic graphic_table graphicRef64036" href="/d/graphic/64036.html" rel="external">table 1</a>) was achieved significantly more often by the patients receiving <a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">ustekinumab</a> (at either dose) compared with those receiving placebo (ACR20 46 versus 23 percent), and responses were maintained at week 52. Clinically and statistically significant improvement in function at week 24 was also achieved more often in the patients receiving ustekinumab at either dose (HAQ-DI increase of at least 0.3 in 48 versus 28 percent). Statistically significant improvements in psoriasis, dactylitis, and enthesitis were also noted.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>After TNF inhibitor failure</strong> – Patients with active PsA despite treatment with a TNF inhibitor were evaluated in another randomized trial with a similar design to that above (the PSUMMIT 2 trial). At week 24, an ACR20 was achieved significantly more often by the patients receiving <a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">ustekinumab</a> (at either dose) compared with those receiving placebo (44 versus 20 percent) [<a href="#rid95">95</a>]. Benefits in composite measures of disease activity and function were sustained at week 52.</p><p></p><p class="bulletIndent2">Serious adverse events occurred in 5.2 percent (15 of 287) of patients treated for 60 weeks with <a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">ustekinumab</a> (11.82 per 100 patient-years). These included serious infections but no cases of tuberculosis and no deaths.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Combined data from these trials also indicated that treatment with <a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">ustekinumab</a> resulted in a statistically significant reduction of radiographic progression of joint injury compared with placebo from baseline to week 24 (modified Sharp-van der Heijde score increase of 0.4 versus 1.0) [<a href="#rid96">96</a>]. Inhibition of progression was maintained at week 52.</p><p></p><p class="bulletIndent1">There are no clinical trials directly comparing <a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">ustekinumab</a> with another therapy for peripheral arthritis in PsA. However, an observational study conducted in Europe suggests that ustekinumab and TNF inhibition have comparable results for patients with peripheral PsA [<a href="#rid97">97</a>]. Another study indicates that ustekinumab may be more effective than TNF inhibitors for enthestitis [<a href="#rid98">98</a>]. Coadministration with MTX does not seem to improve outcomes [<a href="#rid99">99</a>].</p><p></p><p class="headingAnchor" id="H3424674116"><span class="h3">Abatacept</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">Abatacept</a> (CTLA-4-Ig), which is used for the treatment of active PsA, is a selective T-cell costimulation modulator.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration</strong> – It is administered subcutaneously (125 mg once weekly) or intravenously (given initially, two, and four weeks later, then every four weeks thereafter). When administered intravenously, the dose is weight based (500 mg for patients less than 60 kg; 750 mg for patients 60 to 100 kg; 1000 mg for patients greater than 100 kg).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The efficacy and safety of <a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">abatacept</a> for PsA has been demonstrated in randomized trials that have evaluated patients with active PsA.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a six-month study of 170 PsA patients who had previously been treated with immunosuppression (88 percent of whom had been treated with a TNF inhibitor), an ACR20  (<a class="graphic graphic_table graphicRef64036" href="/d/graphic/64036.html" rel="external">table 1</a>) was achieved by more patients treated with <a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">abatacept</a> 10 mg/kg versus placebo (48 versus 19 percent) [<a href="#rid100">100</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a six-month study of 424 PsA patients (60 percent of whom had been treated with a TNF inhibitor), an ACR20 was achieved by more patients treated with subcutaneous <a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">abatacept</a> 125 mg weekly versus placebo (39 versus 22 percent) [<a href="#rid101">101</a>].</p><p></p><p class="bulletIndent2">There was minimal effectiveness for psoriasis in this study. Thus, <a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">abatacept</a> is not ideal for patient with bothersome skin disease.</p><p></p><p class="headingAnchor" id="H2154095438"><span class="h2">Janus kinase inhibitor for patients with concomitant axial disease</span><span class="headingEndMark"> — </span>For patients with concomitant axial disease, we suggest a JAK/signal transducer and activator of transcription (STAT) inhibitor such as <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a> or <a class="drug drug_general" data-topicid="122341" href="/d/drug information/122341.html" rel="external">upadacitinib</a>, both of which have been approved by the FDA for the treatment of PsA and had been shown to be also effective in axial spondyloarthritis, in contrast to IL-23 inhibitors <a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">ustekinumab</a> and <a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">abatacept</a>.</p><p>Precautions regarding the use of JAK inhibitors are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/130611.html" rel="external">"Overview of the Janus kinase inhibitors for rheumatologic and other inflammatory disorders", section on 'Pretreatment screening and precautions'</a> and  <a class="medical medical_review" href="/d/html/130611.html" rel="external">"Overview of the Janus kinase inhibitors for rheumatologic and other inflammatory disorders", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H942503918"><span class="h3">Tofacitinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">Tofacitinib</a>, which is available for the treatment of active PsA that has had an inadequate response to TNF inhibition, is an oral inhibitor of JAK1 and JAK3.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration</strong> – <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">Tofacitinib</a> is administered orally in combination with a nonbiologic oral immunosuppressant, such as MTX. The immediate release formulation is dosed at 5 mg twice daily. The extended release formulation is dosed at 11 mg daily.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The efficacy and safety of <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a> for PsA has been demonstrated in randomized trials that have evaluated patients who have had an inadequate response to a conventional oral immunosuppressant [<a href="#rid102">102</a>] or TNF inhibitor therapy [<a href="#rid103">103</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>In TNF-inhibitor naïve patients</strong> – The Oral Psoriatic Arthritis Trial [OPAL] Broaden enrolled 422 patients with active PsA who had an inadequate response to at least one conventional oral immunosuppressant but were TNF inhibitor-naïve. At three months, an ACR20  (<a class="graphic graphic_table graphicRef64036" href="/d/graphic/64036.html" rel="external">table 1</a>) was achieved by more patients treated with <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a> 5 mg twice daily (50 percent), tofacitinib 10 mg twice daily (61 percent), or <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> 40 mg subcutaneous every two weeks (52 percent) versus placebo (33 percent) [<a href="#rid102">102</a>]. Physical function was also improved at three months. Responses were maintained through month 12, and there were similar rates of serious adverse effects with either of the active drugs. Greater benefit with tofacitinib (5 or 10 mg twice daily) versus placebo was seen by week 2 (ACR20 of 22 and 32 versus 6 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>In patients with inadequate response to TNF inhibition</strong> – In another randomized phase 3 trial (OPAL Beyond), involving 395 patients with active PsA and an inadequate response to a TNF inhibitor, treatment with <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a> (5 mg or 10 mg twice daily) resulted in greater benefit compared with placebo at three months (ACR20 of 50 and 47 versus 24 percent) [<a href="#rid103">103</a>]. Greater improvements in physical function at three months were also observed in the tofacitinib-treated patients. Responses were maintained through the six-month trial. Adverse effects with tofacitinib were similar to those seen in other trials in patients with rheumatoid arthritis or psoriasis.</p><p></p><p class="headingAnchor" id="H4144366110"><span class="h3">Upadacitinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="122341" href="/d/drug information/122341.html" rel="external">Upadacitinib</a>, which is available for the treatment of active PsA that has had an inadequate response to TNF inhibition, is an oral inhibitor of JAK1.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration</strong> – <a class="drug drug_general" data-topicid="122341" href="/d/drug information/122341.html" rel="external">Upadacitinib</a> is administered orally (15 mg daily).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The efficacy and safety of <a class="drug drug_general" data-topicid="122341" href="/d/drug information/122341.html" rel="external">upadacitinib</a> for PsA has been demonstrated in randomized trials that have evaluated patients with active PsA who have had an inadequate response to a conventional oral immunosuppressant [<a href="#rid40">40</a>] or TNF inhibitor therapy [<a href="#rid104">104</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>In biologic-naïve patients</strong> – In the SELECT-PsA 1 trial, 1704 patients with PsA received <a class="drug drug_general" data-topicid="122341" href="/d/drug information/122341.html" rel="external">upadacitinib</a> 15 or 30 mg, placebo, or <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> 40 mg every two weeks [<a href="#rid40">40</a>]. The ACR20  (<a class="graphic graphic_table graphicRef64036" href="/d/graphic/64036.html" rel="external">table 1</a>) response at week 12 was highest in upadacitinib-treated patients (70.6 percent with the 15 mg dose and 78.5 percent with 30 mg dose) compared with adalimumab (65.0 percent) and placebo (36.2 percent). Upadacitinib (at either dose) was also more effective at improving function (ie, HAQ-DI). The percentage of patients who had 75 percent improvement in their skin lesions (ie, PASI75 response), MDA, and resolution of enthesitis, and improvement in the 36-Item Short Form Health Survey physical component summary score (SF-36 PCS) and FACIT-Fatigue scores was significantly higher among the patients taking upadacitinib versus placebo.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>In patients with inadequate response to at least one biologic agent</strong> – In the SELECT-PsA 2 trial, 641 patients were randomized to treatment with <a class="drug drug_general" data-topicid="122341" href="/d/drug information/122341.html" rel="external">upadacitinib</a> 15 or 30 mg orally or placebo [<a href="#rid104">104</a>]. More patients achieved an ACR20 response at week 12 with upadacitinib at either dose (56.9 and 63.8 versus 24.1 percent). At week 24, MDA was achieved by more upadacitinib 15 mg-treated (25.1 percent) and 30 mg-treated patients (25.1 and 28.9 versus 2.8 percent). Benefit was also noted for HAQ-DI, FACIT-Fatigue, and resolution of enthesitis.</p><p></p><p class="headingAnchor" id="H3716221358"><span class="h1">ASSESSMENT OF TREATMENT RESPONSE</span><span class="headingEndMark"> — </span>Typically, patients require up to three months to respond to therapy, but many respond sooner, as illustrated in multiple randomized trials with these drugs. Assessment of the treatment response should be individualized to incorporate other domains of disease activity in addition to arthritis, such as psoriatic skin involvement, dactylitis, and enthesitis, particularly in patients with moderate to severe involvement in these other domains. With respect to the musculoskeletal manifestations, a target of minimal disease activity (MDA) is desirable, but some patients will want to prioritize the treatment of other disease domains. (See  <a class="medical medical_review" href="/d/html/7793.html" rel="external">"Treatment of psoriatic arthritis", section on 'Monitoring'</a> and <a class="local">'Initial considerations'</a> above.)</p><p>Guidelines for drug monitoring are discussed in the table  (<a class="graphic graphic_table graphicRef142892" href="/d/graphic/142892.html" rel="external">table 4</a>).</p><p class="headingAnchor" id="H797104560"><span class="h1">INVESTIGATIONAL TREATMENTS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination therapy</strong> – For patients with severe and treatment-resistant disease, combination therapy may be an important option. However, there are inadequate data to support this approach routinely. </p><p></p><p class="bulletIndent1">The AFFINITY Trial (NCT05071664) is comparing the combination of <a class="drug drug_general" data-topicid="114007" href="/d/drug information/114007.html" rel="external">guselkumab</a> and <a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">golimumab</a> versus guselkumab monotherapy for the treatment of psoriatic arthritis (PsA), but data from this study are not yet available [<a href="#rid105">105</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other interleukin-17 and interleukin-23 inhibitors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="112051" href="/d/drug information/112051.html" rel="external">Brodalumab</a> – Brodalumab is an anti-interleukin 17 (IL-17) receptor antibody that is approved by the US Food and Drug Administration (FDA) for use in psoriasis and has shown efficacy in trials for PsA [<a href="#rid106">106-113</a>].</p><p></p><p class="bulletIndent2">Two phase 3 trials tested the efficacy of <a class="drug drug_general" data-topicid="112051" href="/d/drug information/112051.html" rel="external">brodalumab</a> 140 or 210 mg subcutaneously versus placebo in a total of 962 patients with PsA [<a href="#rid113">113</a>]. Approximately 30 percent had received biologic agents.</p><p></p><p class="bulletIndent2">In a pooled analysis at 16 weeks, American College of Rheumatology (ACR) criteria for 20 percent improvement (ACR20)  (<a class="graphic graphic_table graphicRef64036" href="/d/graphic/64036.html" rel="external">table 1</a>) response rates were 45.8 and 47.9 versus 20.9 percent for 140 and 210 mg versus placebo-treated patients. ACR50 and ACR70 responses were also significantly higher among patients treated with either dose. Benefit was sustained through week 24.</p><p></p><p class="bulletIndent2">Psoriasis Area and Severity Index (PASI) 100 responses (ie, complete resolution of the patient’s skin lesions) were achieved by 40.8 percent of the patients treated with 210 mg, 20.7 percent of those treated with 140 mg, and only 1.9 percent of the placebo-treated patients.</p><p></p><p class="bulletIndent2">Adverse events were not different between the two <a class="drug drug_general" data-topicid="112051" href="/d/drug information/112051.html" rel="external">brodalumab</a> doses and placebo. However, brodalumab trials in PsA were stopped due to a relatively high rate of suicidal ideation and six completed suicides in clinical trials of brodalumab [<a href="#rid114">114</a>]. In the United States, brodalumab can be used for psoriasis after screening for suicidality and enrollment in a Risk Evaluation and Mitigation Strategy (REMS) program [<a href="#rid115">115</a>].</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="117344" href="/d/drug information/117344.html" rel="external">Tildrakizumab</a> – Tildrakizumab is an anti-IL-23 p19 monoclonal antibody that is approved for the treatment of psoriasis [<a href="#rid116">116</a>]. Phase 3 trials in PsA are in progress (NCT04314544, NCT04314531).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other JAK/STAT and TYK2 pathway inhibitors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="139596" href="/d/drug information/139596.html" rel="external">Deucravacitinib</a> – The tyrosine kinase 2 (Tyk2) inhibitor deucravacitinib was studied in a trial of 203 patients with PsA who were randomized to deucravacitinib 6 mg, 12 mg, or placebo [<a href="#rid117">117</a>]. Patients in both deucravacitinib treatment groups were more likely to experience improvement in their peripheral arthritis than patients who received placebo (53 versus 63 versus 32 percent). No serious adverse events were reported in this trial.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Filgotinib</strong> – Filgotinib, a Janus kinase 1 (JAK1) inhibitor, is approved for the treatment of rheumatoid arthritis in Europe, but it was withdrawn from clinical trials in North America based on concerns regarding sperm toxicity in animals [<a href="#rid118">118</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Brepocitinib</strong> – Brepocitinib is a JAK1/TYK2 inhibitor that demonstrated benefit but at this time is not being further pursued [<a href="#rid119">119</a>]. Other TYK2 and JAK1/TYK2 inhibitors are under development.</p><p></p><p class="headingAnchor" id="H3859673361"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112598.html" rel="external">"Society guideline links: Psoriatic arthritis in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/118770.html" rel="external">"Society guideline links: Spondyloarthritis"</a>.)</p><p class="headingAnchor" id="H3534060990"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of minimal peripheral arthritis</strong> – For patients with intermittent joint symptoms that do not significantly impact the patient’s activities, we suggest initiating treatment with symptomatic therapies such as a nonsteroidal antiinflammatory drug (NSAID) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Options include <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> 375 to 500 mg twice daily, <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a> 200 mg twice daily, and <a class="drug drug_general" data-topicid="10295" href="/d/drug information/10295.html" rel="external">meloxicam</a> 15 mg daily  (<a class="graphic graphic_table graphicRef70067" href="/d/graphic/70067.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1">NSAIDs can help control the mild inflammatory symptoms of psoriatic arthritis (PsA) and may also lessen pain and stiffness in associated spondylitis. A concern that NSAIDs may aggravate the skin psoriasis remains unproven. (See <a class="local">'Minimal disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of mild peripheral arthritis</strong> – For patients with up to three active joints or intermittent joint involvement that has failed to respond to NSAIDs, we suggest treating with <a class="drug drug_general" data-topicid="94524" href="/d/drug information/94524.html" rel="external">apremilast</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> (MTX) is an appropriate alternative if apremilast is not available. (See <a class="local">'Mild disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of moderate to severe disease</strong> – For patients with highly active disease (eg, multiple involved joints, erosive disease at presentation, functional limitation) and for patients who fail to improve with <a class="drug drug_general" data-topicid="94524" href="/d/drug information/94524.html" rel="external">apremilast</a> or MTX, we suggest treatment with a tumor necrosis factor (TNF) inhibitor (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). TNF inhibitors have demonstrated efficacy in PsA. Other agents may be similarly effective; however, comparative efficacy trials are lacking.</p><p></p><p class="bulletIndent1">The efficacy of all TNF inhibitors for PsA are comparable, and the choice of agent is largely determined by patient and payor preferences. (See <a class="local">'Moderate to severe disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Failure of initial TNF inhibitor</strong> – For patients who experience loss of efficacy following an initial response to TNF inhibition, we suggest switching to another TNF inhibitor or to an interleukin 17 (IL-17) inhibitor (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Failure of initial TNF inhibitor'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Failure of TNF and IL-17 inhibition</strong> – For patients who have failed to respond to TNF and IL-17 inhibition, we suggest the following approach (see <a class="local">'Patients without concomitant axial disease'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For patients without concomitant axial disease</strong> – We suggest an IL-23 inhibitor (ie, <a class="drug drug_general" data-topicid="114007" href="/d/drug information/114007.html" rel="external">guselkumab</a>, <a class="drug drug_general" data-topicid="121112" href="/d/drug information/121112.html" rel="external">risankizumab</a>, or <a class="drug drug_general" data-topicid="138686" href="/d/drug information/138686.html" rel="external">bimekizumab</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients who cannot use an IL-23 inhibitor (eg., due to intolerance), <a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">ustekinumab</a> is a reasonable choice. <a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">Abatacept</a> can be used if the patient has minimal or no psoriasis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For patients with concomitant axial disease</strong> – We use a JAK inhibitor (eg, <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a>, <a class="drug drug_general" data-topicid="122341" href="/d/drug information/122341.html" rel="external">upadacitinib</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment of treatment response</strong> – Patients may require up to three months to respond to therapy. Patient assessment should consider all of the domains of PsA (ie, peripheral arthritis, axial arthritis, dactylitis, enthesitis, skin, and nails). (See <a class="local">'Assessment of treatment response'</a> above.)</p><p></p><p class="bulletIndent1">Guidelines for drug monitoring are discussed in the table  (<a class="graphic graphic_table graphicRef142892" href="/d/graphic/142892.html" rel="external">table 4</a>).</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bruce IN, Gladman DD. Psoriatic arthritis: recognition and management. BioDrugs 1998; 9:271.</a></li><li><a class="nounderline abstract_t">Cuéllar ML, Citera G, Espinoza LR. Treatment of psoriatic arthritis. Baillieres Clin Rheumatol 1994; 8:483.</a></li><li><a class="nounderline abstract_t">Sarzi-Puttini P, Santandrea S, Boccassini L, et al. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 2001; 19:S17.</a></li><li><a class="nounderline abstract_t">Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71:4.</a></li><li><a class="nounderline abstract_t">Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 2016; 68:1060.</a></li><li><a class="nounderline abstract_t">Goodfield M. Skin lesions in psoriasis. Baillieres Clin Rheumatol 1994; 8:295.</a></li><li><a class="nounderline abstract_t">Abel EA, DiCicco LM, Orenberg EK, et al. Drugs in exacerbation of psoriasis. J Am Acad Dermatol 1986; 15:1007.</a></li><li><a class="nounderline abstract_t">Eder L, Chandran V, Ueng J, et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology (Oxford) 2010; 49:1367.</a></li><li><a class="nounderline abstract_t">Tomi NS, Kränke B, Aberer E. Staphylococcal toxins in patients with psoriasis, atopic dermatitis, and erythroderma, and in healthy control subjects. J Am Acad Dermatol 2005; 53:67.</a></li><li><a class="nounderline abstract_t">Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014; 73:1020.</a></li><li><a class="nounderline abstract_t">Fala L. Otezla (Apremilast), an Oral PDE-4 Inhibitor, Receives FDA Approval for the Treatment of Patients with Active Psoriatic Arthritis and Plaque Psoriasis. Am Health Drug Benefits 2015; 8:105.</a></li><li class="breakAll">FDA NEWS RELEASE. FDA approves Otezla to treat psoriatic arthritis. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm390091.htm (Accessed on March 31, 2014).</li><li><a class="nounderline abstract_t">Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol 2008; 35:469.</a></li><li><a class="nounderline abstract_t">Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 2012; 51:1368.</a></li><li><a class="nounderline abstract_t">Lie E, van der Heijde D, Uhlig T, et al. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69:671.</a></li><li><a class="nounderline abstract_t">Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016; 75:499.</a></li><li><a class="nounderline abstract_t">Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68:1387.</a></li><li><a class="nounderline abstract_t">Mease PJ, Gladman DD, Collier DH, et al. Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial. Arthritis Rheumatol 2019; 71:1112.</a></li><li><a class="nounderline abstract_t">Gelfand JM, Wan J, Zhang H, et al. Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: A population-based study. J Am Acad Dermatol 2021; 84:1636.</a></li><li><a class="nounderline abstract_t">Yongpisarn T, Namasondhi A, Iamsumang W, et al. Liver fibrosis prevalence and risk factors in patients with psoriasis: A systematic review and meta-analysis. Front Med (Lausanne) 2022; 9:1068157.</a></li><li><a class="nounderline abstract_t">Dougados M, vam der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995; 38:618.</a></li><li><a class="nounderline abstract_t">Levy JJ, Paulus HE, Barnett EV, et al. A double-blind controlled evaluation of azathioprine treatment in the rheumatoid arthritis and psoriatic arthritis. Arthritis Rheum 1972; 15:116.</a></li><li><a class="nounderline abstract_t">Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004; 50:1939.</a></li><li><a class="nounderline abstract_t">Scarpa R, Manguso F, Oriente A, et al. Leflunomide in psoriatic polyarthritis. J Clin Rheumatol 2002; 8:286.</a></li><li><a class="nounderline abstract_t">Liang GC, Barr WG. Open trial of leflunomide for refractory psoriasis and psoriatic arthritis. J Clin Rheumatol 2001; 7:366.</a></li><li><a class="nounderline abstract_t">Behrens F, Finkenwirth C, Pavelka K, et al. Leflunomide in psoriatic arthritis: results from a large European prospective observational study. Arthritis Care Res (Hoboken) 2013; 65:464.</a></li><li><a class="nounderline abstract_t">Asiri A, Thavaneswaran A, Kalman-Lamb G, et al. The effectiveness of leflunomide in psoriatic arthritis. Clin Exp Rheumatol 2014; 32:728.</a></li><li><a class="nounderline abstract_t">Salvarani C, Macchioni P, Olivieri I, et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001; 28:2274.</a></li><li><a class="nounderline abstract_t">Fraser AD, van Kuijk AW, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005; 64:859.</a></li><li><a class="nounderline abstract_t">Gupta AK, Grober JS, Hamilton TA, et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 1995; 22:894.</a></li><li><a class="nounderline abstract_t">Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999; 42:2325.</a></li><li><a class="nounderline abstract_t">Jones G, Crotty M, Brooks P. Interventions for psoriatic arthritis. Cochrane Database Syst Rev 2000; :CD000212.</a></li><li><a class="nounderline abstract_t">Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006; 33:1422.</a></li><li><a class="nounderline abstract_t">Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39:2013.</a></li><li><a class="nounderline abstract_t">Rahman P, Gladman DD, Cook RJ, et al. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol 1998; 25:1957.</a></li><li><a class="nounderline abstract_t">Veale DJ, Ho M, Morley KD. Sulphasalazine-induced lupus in psoriatic arthritis. Br J Rheumatol 1995; 34:383.</a></li><li><a class="nounderline abstract_t">Jullien D, Wolkenstein P, Roupie E, et al. Toxic epidermal necrolysis after sulfasalazine treatment of mild psoriatic arthritis: warning on the use of sulfasalazine for a new indication. Arthritis Rheum 1995; 38:573.</a></li><li><a class="nounderline abstract_t">Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 2022; 18:465.</a></li><li><a class="nounderline abstract_t">Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis 2020; 79:123.</a></li><li><a class="nounderline abstract_t">McInnes IB, Anderson JK, Magrey M, et al. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. N Engl J Med 2021; 384:1227.</a></li><li><a class="nounderline abstract_t">McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet 2020; 395:1496.</a></li><li><a class="nounderline abstract_t">Mease PJ, Gladman DD, Gomez-Reino JJ, et al. Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials. ACR Open Rheumatol 2020; 2:459.</a></li><li><a class="nounderline abstract_t">Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356:385.</a></li><li><a class="nounderline abstract_t">Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50:2264.</a></li><li><a class="nounderline abstract_t">Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006; 33:712.</a></li><li><a class="nounderline abstract_t">de Vlam K, Lories RJ, Janssen S. Sustained improvement in clinical measures of psoriatic arthritis in etanercept: 3-year results in an inception cohort. (Abstract) Ann Rheum Dis 2008; 67(suppl II):525.</a></li><li><a class="nounderline abstract_t">Van Den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002; 46:755.</a></li><li><a class="nounderline abstract_t">Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52:1227.</a></li><li><a class="nounderline abstract_t">Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64:1150.</a></li><li><a class="nounderline abstract_t">Kavanaugh A, Antoni CE, Gladman D, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006; 65:1038.</a></li><li><a class="nounderline abstract_t">Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008; 35:869.</a></li><li><a class="nounderline abstract_t">Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52:3279.</a></li><li><a class="nounderline abstract_t">Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007; 56:476.</a></li><li><a class="nounderline abstract_t">Gladman DD, Mease PJ, Choy EH, et al. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther 2010; 12:R113.</a></li><li><a class="nounderline abstract_t">Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007; 34:1040.</a></li><li><a class="nounderline abstract_t">Van den Bosch F, Manger B, Goupille P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 2010; 69:394.</a></li><li><a class="nounderline abstract_t">Mease PJ, Signorovitch J, Yu AP, et al. Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials. Dermatology 2010; 220:1.</a></li><li><a class="nounderline abstract_t">Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009; 60:976.</a></li><li><a class="nounderline abstract_t">Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 2012; 64:2504.</a></li><li><a class="nounderline abstract_t">Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014; 73:48.</a></li><li><a class="nounderline abstract_t">van der Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis 2014; 73:233.</a></li><li><a class="nounderline abstract_t">Heiberg MS, Kaufmann C, Rødevand E, et al. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Ann Rheum Dis 2007; 66:1038.</a></li><li><a class="nounderline abstract_t">Carmona L, Gómez-Reino JJ, BIOBADASER Group. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006; 8:R72.</a></li><li><a class="nounderline abstract_t">Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008; 59:234.</a></li><li><a class="nounderline abstract_t">Saad AA, Ashcroft DM, Watson KD, et al. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 2009; 11:R52.</a></li><li><a class="nounderline abstract_t">Glintborg B, Østergaard M, Dreyer L, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011; 63:382.</a></li><li><a class="nounderline abstract_t">Eder L, Chandran V, Schentag CT, et al. Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort. Rheumatology (Oxford) 2010; 49:1361.</a></li><li><a class="nounderline abstract_t">Saougou I, Markatseli TE, Papagoras C, et al. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study. Semin Arthritis Rheum 2011; 40:398.</a></li><li><a class="nounderline abstract_t">Goulabchand R, Mouterde G, Barnetche T, et al. Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis 2014; 73:414.</a></li><li><a class="nounderline abstract_t">Michaela Koehm, Tanja Rossmainth, Ann C Foldenauer, et al. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial. Lancet Rheumatol 2022; 5:E14.</a></li><li><a class="nounderline abstract_t">Fagerli KM, Lie E, van der Heijde D, et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2014; 73:132.</a></li><li><a class="nounderline abstract_t">Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med 2014; 371:326.</a></li><li><a class="nounderline abstract_t">Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; 386:541.</a></li><li><a class="nounderline abstract_t">Nguyen T, Churchill M, Levin R, et al. Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study. J Rheumatol 2022; 49:894.</a></li><li><a class="nounderline abstract_t">Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 2017; 76:79.</a></li><li><a class="nounderline abstract_t">Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet 2017; 389:2317.</a></li><li><a class="nounderline abstract_t">Smolen JS, Mease P, Tahir H, et al. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. Ann Rheum Dis 2020; 79:1310.</a></li><li><a class="nounderline abstract_t">McInnes IB, Asahina A, Coates LC, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet 2023; 401:25.</a></li><li><a class="nounderline abstract_t">Merola JF, Landewé R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet 2023; 401:38.</a></li><li><a class="nounderline abstract_t">Ritchlin CT, Kavanaugh A, Merola JF, et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet 2020; 395:427.</a></li><li><a class="nounderline abstract_t">Coates LC, McInnes IB, Merola JF, et al. Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study. Arthritis Rheumatol 2022; 74:1959.</a></li><li><a class="nounderline abstract_t">Mease PJ, Asahina A, Gladman DD, et al. Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE. Rheumatology (Oxford) 2023; 62:617.</a></li><li><a class="nounderline abstract_t">Strober B, Coates LC, Lebwohl MG, et al. Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis. Drug Saf 2024; 47:39.</a></li><li><a class="nounderline abstract_t">Deodhar A, Gottlieb AB, Boehncke WH, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2018; 391:2213.</a></li><li><a class="nounderline abstract_t">Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2020; 395:1115.</a></li><li><a class="nounderline abstract_t">Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2020; 395:1126.</a></li><li><a class="nounderline abstract_t">Coates LC, Ritchlin CT, Gossec L, et al. Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. Rheumatology (Oxford) 2023; 62:606.</a></li><li><a class="nounderline abstract_t">Mease PJ, McInnes IB, Tam LS, et al. Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis. Rheumatology (Oxford) 2023; 62:1417.</a></li><li><a class="nounderline abstract_t">Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis 2022; 81:225.</a></li><li><a class="nounderline abstract_t">Kristensen LE, Soliman AM, Papp K, et al. Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1. Rheumatology (Oxford) 2023; 62:629.</a></li><li><a class="nounderline abstract_t">Östör A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis 2022; 81:351.</a></li><li class="breakAll">Ustekinumab injection. US Food and Drug Administration (FDA) approved product information. Revised June 2018. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125261s147lbl.pdf (Accessed on January 22, 2024).</li><li><a class="nounderline abstract_t">McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382:780.</a></li><li><a class="nounderline abstract_t">Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373:633.</a></li><li><a class="nounderline abstract_t">Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014; 73:990.</a></li><li><a class="nounderline abstract_t">Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 2014; 73:1000.</a></li><li><a class="nounderline abstract_t">Gossec L, Siebert S, Bergmans P, et al. Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study. Ann Rheum Dis 2023; 82:496.</a></li><li><a class="nounderline abstract_t">Araujo EG, Englbrecht M, Hoepken S, et al. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum 2019; 48:632.</a></li><li><a class="nounderline abstract_t">Koehm M, Rossmanith T, Foldenauer AC, et al. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial. Lancet Rheumatol 2023.</a></li><li><a class="nounderline abstract_t">Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011; 63:939.</a></li><li><a class="nounderline abstract_t">Mease PJ, Gottlieb AB, van der Heijde D, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis 2017; 76:1550.</a></li><li><a class="nounderline abstract_t">Mease P, Hall S, FitzGerald O, et al. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med 2017; 377:1537.</a></li><li><a class="nounderline abstract_t">Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. N Engl J Med 2017; 377:1525.</a></li><li><a class="nounderline abstract_t">Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis 2021; 80:312.</a></li><li class="breakAll">ClinicalTrials.gov. A study of guselkumab and golimumab combination therapy in participants with active psoriatic arthritis (AFFINITY). https://clinicaltrials.gov/ct2/show/NCT05071664 (Accessed on May 24, 2023).</li><li><a class="nounderline abstract_t">McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014; 73:349.</a></li><li><a class="nounderline abstract_t">Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med 2015; 373:1329.</a></li><li><a class="nounderline abstract_t">McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 386:1137.</a></li><li><a class="nounderline abstract_t">Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366:1190.</a></li><li><a class="nounderline abstract_t">Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2:52ra72.</a></li><li><a class="nounderline abstract_t">Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366:1181.</a></li><li><a class="nounderline abstract_t">Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014; 370:2295.</a></li><li><a class="nounderline abstract_t">Mease PJ, Helliwell PS, Hjuler KF, et al. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Ann Rheum Dis 2021; 80:185.</a></li><li><a class="nounderline abstract_t">Foulkes AC, Warren RB. Brodalumab in psoriasis: evidence to date and clinical potential. Drugs Context 2019; 8:212570.</a></li><li class="breakAll">SILIQ REMS. https://siliqrems.com/ (Accessed on January 17, 2024).</li><li><a class="nounderline abstract_t">Reich K, Warren RB, Iversen L, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol 2020; 182:605.</a></li><li><a class="nounderline abstract_t">Mease PJ, Deodhar AA, van der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis 2022; 81:815.</a></li><li><a class="nounderline abstract_t">Reinisch W, Hellstrom W, Dolhain RJEM, et al. Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies. Ann Rheum Dis 2023; 82:1049.</a></li><li><a class="nounderline abstract_t">Mease P, Helliwell P, Silwinska-Stanczyk P, et al. Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial. Arthritis Rheumatol 2023; 75:1370.</a></li></ol></div><div id="topicVersionRevision">Topic 141133 Version 2.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18020565" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Psoriatic arthritis: recognition and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8076399" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Treatment of psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11296544" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21953336" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26749174" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8076389" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Skin lesions in psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2878015" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Drugs in exacerbation of psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20388640" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Predictors of response to intra-articular steroid injection in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15965423" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Staphylococcal toxins in patients with psoriasis, atopic dermatitis, and erythroderma, and in healthy control subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24595547" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26629274" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Otezla (Apremilast), an Oral PDE-4 Inhibitor, Receives FDA Approval for the Treatment of Patients with Active Psoriatic Arthritis and Plaque Psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26629274" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Otezla (Apremilast), an Oral PDE-4 Inhibitor, Receives FDA Approval for the Treatment of Patients with Active Psoriatic Arthritis and Plaque Psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18085735" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22344575" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A randomized placebo-controlled trial of methotrexate in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19740904" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26644232" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18952643" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Treatment recommendations for psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30747501" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33607181" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: A population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36590962" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Liver fibrosis prevalence and risk factors in patients with psoriasis: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7748217" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A double-blind controlled evaluation of azathioprine treatment in the rheumatoid arthritis and psoriatic arthritis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15188371" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17041391" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Leflunomide in psoriatic polyarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17039176" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Open trial of leflunomide for refractory psoriasis and psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23042698" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Leflunomide in psoriatic arthritis: results from a large European prospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25151858" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The effectiveness of leflunomide in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11669169" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15528283" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8587078" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10555027" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10908464" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Interventions for psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16724372" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Therapies for peripheral joint disease in psoriatic arthritis. A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8961906" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9779850" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The use of sulfasalazine in psoriatic arthritis: a clinic experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7788157" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Sulphasalazine-induced lupus in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7718014" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Toxic epidermal necrolysis after sulfasalazine treatment of mild psoriatic arthritis: warning on the use of sulfasalazine for a new indication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35761070" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31563894" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33789011" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32386593" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32710493" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10972371" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15248226" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16463435" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Sustained improvement in clinical measures of psoriatic arthritis in etanercept: 3-year results in an inception cohort</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11920412" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15818699" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15677701" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16439444" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18381786" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16200601" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17265483" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20537151" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17444593" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19815494" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19940437" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19333944" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22378566" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23942868" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23942869" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17213251" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16620398" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18240258" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19356232" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21279995" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factorαtherapy: results from the nationwide Danish DANBIO registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20385615" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20843542" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23355079" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23291385" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25007392" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Secukinumab in plaque psoriasis--results of two phase 3 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26072109" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35428722" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27553214" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28551073" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32660977" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36493791" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36495881" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-αinhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32035552" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35829656" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35789257" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37906417" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29893222" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32178765" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFαinhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32178766" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35766811" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36102818" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34911706" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35801915" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34815219" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34815219" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23769296" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19217154" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24482301" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24553909" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36600178" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30037432" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21128258" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28473423" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29045212" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29045207" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33272960" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33272960" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23361084" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26422723" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26135703" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22455413" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20926833" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22455412" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24918373" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33106286" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31024633" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Brodalumab in psoriasis: evidence to date and clinical potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31024633" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Brodalumab in psoriasis: evidence to date and clinical potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31218661" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35241426" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37137672" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37194394" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
